Ge Long Hui·2026-01-30 02:44Core Viewpoint - UBS reports that Tigermed has issued a performance forecast, expecting a 1% year-on-year growth in revenue for 2025, indicating a 6.4% year-on-year growth in Q4 revenue to 72.9 billion, with a median increase of 39.6% exceeding both UBS and market expectations [1] Revenue and Profit Forecast - The company anticipates net profit attributable to shareholders to be between 830 million and 1.23 billion, representing a year-on-year increase of 105% to 204, which is below UBS and market expectations [1] - The pricing of new orders signed in 2025 is expected to stabilize but still decline year-on-year, putting pressure on profit margins [1] Market Signals and Management Guidance - The company emphasizes a recovery in clinical research demand [1] - UBS is focused on signals of price recovery for new orders in 2026, as well as management's guidance on revenue and profit for 2026 [1] - UBS has set a target price of 57.1 HKD and maintains a "Buy" rating [1]